【IHH 5225 交流专区】综合保健控股

icy97

IHH HEALTHCARE BERHAD

Type	Announcement
Subject	OTHERS
Description	Acquisition of 60% equity interest in Hui Xing Hospital Investment Management Co. Ltd by Shanghai Mai Kang Hospital Investment Management Co., Ltd, an indirect wholly-owned subsidiary of IHH Healthcare Berhad ("the Company")
Pursuant to Paragraph 9.19(23) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of the Company is pleased to announce that Shanghai Mai Kang Hospital Investment Management Co., Ltd (“Shanghai Mai Kang”), an indirect wholly-owned subsidiary of the Company, had on 13 August 2013 acquired 60% equity interests in Hui Xing Hospital Investment Management Co. Ltd (“Hui Xing”) for a consideration of RMB12 million (equivalent to RM6,387,736*) (“Acquisition”).      Hui Xing is a company registered in the People’s Republic of China with a registered capital of RMB20 million. The principal activity of Hui Xing is investment in healthcare industry. The Acquisition is not expected to have any material effect on the earnings or net assets of the IHH Group for the current financial year ending 31 December 2013. None of the Directors and/or major shareholders or persons connected to them, have any interest, direct or indirect in the Acquisition. * Based on the exchange rate of RM1.00:RMB1.8786 on 13 August 2013 as set out in the Bank Negarawebsite, subject to rounding.

icy97

綜合保健次季賺1.57億

2013-08-28 11:25      
（吉隆坡27日訊）由於前期脫售醫療套房兌現1億9千360萬令吉一次性收益推高比較基礎，綜合保健（IHH，5225，主板貿服組）截至2013年6月30日止第二季淨利下跌60.7%至1億5千675萬7千令吉，上半年淨利則挫45.55%至2億8千403萬令吉。

第二季營業額則報16億8千萬令吉，下滑31.95%，上半年營業額33億零460萬令吉，走疲16.36%。

扣除前期脫售醫療套房所兌現的12億零960萬令吉營業額和1億9千360萬令吉淨利，綜合保健控股第二季營業額成長14%，營運盈利則上揚20%。

該公司董事經理林焯彬醫生透過文告說，公司旗下各業務臂膀次季表現持續轉強，其中百匯班台營業額按年成長11%，土耳其Acibadem醫院則成長18%，教育業務臂膀－－國際醫療大學（IMU）則寫下22%成長。

同時，他強調集團在積極找尋成長機會之際，也對各國匯率風險保持警惕，而且在各國業務皆面對專業醫療人員短缺情況下，雇員開銷可能上揚，集團將採取積成本控制措施應變。

“集團在海內外皆握有健全的新計劃在手，預料這些計劃將帶動未來業務成長，無論如何，這些新計劃短期內可能涉及額外設立成本、貶值和融資成本，侵蝕整體賺幅，但排除不可預見情況，預料未來財務表現繼續令人滿意。”（星洲日報／財經）

SUMMARY OF KEY FINANCIAL INFORMATION 30/06/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/06/2013	30/06/2012	30/06/2013	30/06/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	1,680,002	2,688,645	3,304,600	3,950,816
2	Profit/(loss) before tax	208,141	502,512	421,729	720,760
3	Profit/(loss) for the period	180,033	416,353	347,325	590,254
4	Profit/(loss) attributable to ordinary equity holders of the parent	156,757	398,897	284,030	521,668
5	Basic earnings/(loss) per share (Subunit)	1.93	6.44	3.51	8.54
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.1600		2.1300

icy97

綜合保健第三季不看好

2013-08-28 17:41      
（吉隆坡28訊）綜合保健（IHH，5225，主板貿服組）次季業績表現普遍達到市場預測；分析員認為，今年第三季表現料受新元強勢、伊斯蘭齋戒月、華人中元“鬼”節，以及土耳其炎熱夏天等利空影響而走軟，加上股價已經走高，使分析員未能上調其偏低的評級。

股價一度下跌6.18%

次季業績欠佳，前景蒙塵，因馬幣和印尼盾兌新元疲軟，預料衝擊未來季度表現，該公司股價今日暴跌，一度大跌25仙或6.18%至3令吉79仙，收市報3令吉84仙，挫20仙。

大眾研究說，隨著最近新元匯率走強，預料將負面影響區域外國醫藥遊客到訪綜合保健旗下新加坡醫院求醫，第三季業績表現料也受到伊斯蘭教徒齋戒月，及華人中元節的影響，因是較為忌諱進行求醫的傳統季節。

大馬研究指出，綜合保健第三季業績，料因新加坡及大馬傳統季節性淡季，以及土耳其炎熱夏天（6月至9月）的傳統淡季的影響。而新元兌印尼盾匯率走高，料也負面影響印尼醫藥遊客，到新加坡醫院求醫的需求。

馬銀行研究認為，綜合保健相當依賴旗下新加坡業務，占重复淨利的44%，特別是醫藥旅遊客戶數目顯著，占病人總數的40%至50%，主要來自區域市場，特別是印尼遊客。隨著近期區域主要貨幣兌美元匯率走貶，相信短期里將打擊市場需求。

丰隆研究表示，隨著次季業績出爐，基於最新趨勢，營運數據及利差等回歸模式基礎後，將2013至2015年每股淨利，分別下調9.2%，4.9%，及2.7%。

丰隆指出，綜合保健潛在優勢，包括強勁品牌、醫藥旅遊蓬勃、高素質醫藥保健服務需求走高，以及持續擴充計劃等；預測今年淨利為6億3千900萬，2014年為7億8千700萬，2015年為8億8千800萬令吉。

大眾研究在營運成本走高利空下，將2013至2015年財政年淨利預測下調15至23%，分別至6億零520萬，6億8千150萬，以及7億3千160萬令吉。（星洲日報／財經）

icy97

综合保健：新元大起　赴狮城医疗游客减

二零一三年八月二十九日 凌晨三时三十分
（吉隆坡28日讯）由于新加坡元升值，综合保健控股有限公司（IHH，5225，贸易服务组）的新加坡经营预料短期内将带来较少的贡献，因医疗旅游人士将减少前往该岛国。

该保健公司董事经理林焯彬医生表示：“我们新加坡医疗约18%至20%的病患是来自印尼。货币波动可能影响前来新加坡的病患数字，新加坡的海外病患已经下滑，但当地病患则增加。”

他补充：“它并不会实质上影响我们，我们现在并不会面对困境。”

林焯彬认为，该保健集团现在将看到市场的微幅趋软，但对这只是一项短期影响的希望依然看好，一旦对美国缩小债券购买计划的消息缓和后恢复稳定。

令吉和印尼盾兑新元汇率都已滑落。周二，新元兑相关货币企于52周新高。它现已升值至兑2.59令吉和触及8831.23印尼盾的高峰。

在截至6月30日止第2季，综合保健的净盈利比前一年降低约60%至1亿5600万令吉，主要是因为之前的表现纳入了脱售医疗套房所得的一次过赚益。

综合保健也在期间拨出5372万令吉的额外项目。这包括相关收购Acibadem控股的开销，以及脱售印尼Pantai Bethany医疗国际的赚益。

扣除上述医疗套房脱售的一次过赚益和额外项目后，该医疗集团的净盈利在第2财季实际上增长了60%至1亿8870万令吉。

综合保健控股来自主要市场，即新加坡和马来西亚的病患数量和收益，出现按季萎缩。该集团强调，新加坡的每名病患平均收益，增5.4%至2万829令吉，而于马来西亚则提高4%至4465令吉。[光华日报财经]

icy97

陈诗龙明年任IHH董事经理

财经新闻  财经 2013-10-15 11:00
（吉隆坡14日讯）综合保健控股（IHH，5225，主板贸服股）宣布，该公司董事经理林焯彬将在年底卸任，并由现任执行董事陈诗龙接棒。

综合保健控股向马交所报备，配合该公司的转型计划，林焯彬将在12月31日卸任董事经理一职，并在2014年1月1日调任为非执行高级顾问。

现年66岁的林焯彬指出，他与董事部并无意见分歧，而且其卸任董事经理一职，也没有股东需要担忧的事宜。

随着林焯彬卸任，现任执行董事陈诗龙，将被擢升为董事经理，2014年1月1日起生效。

陈诗龙也将继续担任百汇班底有限公司（Parkway Pantai）董事经理兼总执行长，及百汇控股（ParkwayHoldings）董事经理的职位。

这两家公司都是综合保健控股间接独资子公司。

根据文告，现年44岁的陈诗龙是新加坡人，在保健领域有超过20年经验，并在去年4月受委为执行董事。[南洋网财经]

Date of change	31/12/2013
Name	Dr Lim Cheok Peng
Age	66
Nationality	Malaysian
Type of change	Redesignation
Previous Position	Managing Director
New Position	Others
Directorate	Non Independent & Non Executive
Qualifications	Dr Lim Cheok Peng graduated from the University of Singapore with an MBBS in 1972 and obtained a Master of Medicine (Internal Medicine) from the same university in 1976. In 1977, he became a Member of the Royal College of Physicians of the United Kingdom and later became a Fellow of the Royal College of Physicians and Surgeons of Glasgow and Edinburgh.
Working experience and occupation	Dr Lim has extensive experience both as a medical practitioner and in managing hospital businesses. He was one of a group of doctors who started the Kuantan Specialist Centre, a 100-bed private hospital in Kuantan, Pahang. In 1985, Dr Lim practised internal medicine and cardiology at Mount Elizabeth Hospital and then went on to become a consultant to Parkway Holdings Limited ("PHL") in 1987. From 1990 to 2000, Dr Lim was the Managing Director ("MD") of Gleneagles International and Head of Healthcare Division of PHL. In 2000, he took on the role of MD of PHL and was subsequently appointed as its Executive Vice Chairman in 2010. Dr Lim has been instrumental in expanding PHL’s healthcare business in Singapore and abroad. In 2011, he joined the Company as Executive Director to lead its management team and was re-designated to the post of MD in March 2012.
Directorship of public companies (if any)	Directorship of public company in Malaysia -------------------------------------------------- Pantai Holdings Berhad, an indirect wholly owned subsidiary of the Company.
Family relationship with any director and/or major shareholder of the listed issuer	Nil
Any conflict of interests that he/she has with the listed issuer	Nil
Details of any interest in the securities of the listed issuer or its subsidiaries	Interest in the securities of IHH Healthcare Berhad as at 14 October 2013 -------------------------------------------------------------------- Ordinary Shares - Direct   : 26,308,000 shares - Indirect :      7,000 shares Long Term Incentive Plan : 3,699,000 units Equity Participation Plan : 18,750,000 units

Date of change	01/01/2014
Name	Dr Tan See Leng
Age	48
Nationality	Singaporean
Type of change	Redesignation
Previous Position	Executive Director
New Position	Managing Director
Directorate	Executive
Qualifications	Dr Tan See Leng holds an MBBS and a Master of Medicine (Family Medicine) from the National University of Singapore. He also has an MBA from The University of Chicago Booth Graduate School of Business.
Working experience and occupation	Dr Tan has over 20 years of experience in the healthcare industry. After founding a private primary healthcare group in Singapore, Dr Tan joined Parkway Holdings Limited ("PHL") in 2004 as Chief Operating Officer of Mount Elizabeth Hospital. In 2006, he was appointed Senior Vice President, International Operations of PHL before being seconded to Pantai Holdings Berhad as Chief Executive Officer (“CEO”) of the Hospitals Division. He held the position of Executive Vice President of Singapore and Malaysia Operations in 2009, until he became the Managing Director ("MD") and CEO of PHL in 2010. Following the restructuring of IHH Healthcare Berhad Group in 2011, he assumed his current position as the Group CEO and MD of Parkway Pantai Limited ("PPL"), an indirect wholly owned subsidiary of the Company. In April 2012, he was appointed Executive Director of the Company. Dr Tan currently serves as a Council Member of the Singapore-Guangdong Collaboration Council. He was reappointed Adjunct Assistant Professor of Duke-NUS Graduate Medical School Singapore, Office of Education for a three-year term until 2015.
Directorship of public companies (if any)	Directorship of public company in Malaysia -------------------------------------------------- Pantai Holdings Berhad, an indirect wholly owned subsidiary of the Company
Family relationship with any director and/or major shareholder of the listed issuer	Nil
Any conflict of interests that he/she has with the listed issuer	Nil
Details of any interest in the securities of the listed issuer or its subsidiaries	Interest in the securities of IHH Healthcare Berhad as at 14 October 2013 ------------------------------------------------------------------- Ordinary Shares of RM1.00 each - Direct   : 17,018,000 shares Long Term Incentive Plan : 3,311,000 units Equity Participation Plan : 18,750,000 units

icy97

人事變動透明‧綜合保健運作照常

2013-10-16 18:24

■新聞

綜合保健控股（IHH,5225,主板貿服組）委任執行董事陳士龍（音譯）為董事經理，而原董事經理林焯彬醫生將退居非執行資深顧問。

林焯彬將於今年12月31日正式卸任董事經理一職，而陳士龍將在明年1月1日繼任，該人事調動為該公司的重整計劃的一部份。

■分析

分析員認為，最新人事變動非常透明，加上該公司的管理層強穩，內部管制良好，相信公司運作不會受到影響。

安聯研究指出，雖然林焯彬即將卸任，讓他們大感意外，但在上述理由的支持下，該公司一切業務將照常運作。

“既然林焯彬卸任不至於影響該公司的基本運作，我們維持綜合保健控股的｀中和’評級和目標價3令吉60仙。”

安聯研究補充，該公司即將在下月公佈第三季業績，屆時他們將考慮重估其評級和目標價。

週三閉市，綜合保健控股漲1仙，收4令吉21仙。（星洲日報／財經）

icy97

国库完成发售6亿新元可转换伊债

財经 2013年10月18日
（吉隆坡18日讯）国库控股宣佈已经通过纳闽公司－－Indah资本公司（Indah Capital Ltd）完成了总值6亿新元（15亿2400万令吉）的可转换新元伊斯兰债券发售。

国库控股在文告中指出，这批新元伊斯兰债券的发售规模比初定计划大，其初步计划所发售的规模为5亿新元（12亿7000万令吉）。

转换IHH股票

这批债券可转换为综合医疗控股（IHH，5225，主板贸服股）的股票。

以市值计算，综合医疗控股是全球最大的医疗服务供应商之一。

国库控股在文告表示，这是国库控股首项以新元发售的负收益率可转换伊斯兰债券，同时也是首项与医疗保健领域成长掛勾的伊斯兰债券。

国库控股董事经理丹斯里阿兹曼莫达通过文告说，在2013年上半年，综合医疗控股在新加坡的营运为该集团的总营业额和税前盈利（EBITDA）分別做出约35%和30%的贡献（以新元计价）。

「这项交易成功完成进一步巩固了大马成为全球伊斯兰金融中心的地位。伊斯兰金融已成为全球金融体系中不可或缺的一部份，大马在这充满活力的市场中脱颖而出，成为领跑者，並不断地方推出更创新、更有深度的產品。」

同时，他也指出，这项新元伊斯兰债券的发售符合国库控股的集资策略，以及长期逐步脱售其投资资產的承诺。

文告称，这批新元伊斯兰债券为期5年，投资者可选择在第三年结束后行使他们的权益。

在行使权益之下，这批新元伊斯兰债券的持有人可转换共3亿1140万股综合医疗控股的股票，这占综合医疗控股当前缴足资本的3.8%。

联昌国际银行、德意志银行和渣打银行为这项可转换伊斯兰债券交易的联合账簿管理人及联合主理。 [东方日报财经]

icy97

綜合保健財測不變

2013-11-12 17:10      
（吉隆坡12日訊）綜合保健控股（IHH，5225，主板貿服組）新醫院及區域市場拓展計劃支撐中長期盈利前景，不過份析員認為多數正面因素已反映於股價，維持財測不變。

股價已反映正面因素

大馬研究指出，綜合保健控股新醫院及拓展計劃進展順利，未來幾年受大馬38%及29%病床量增長支撐，中長期盈利前景成長堅挺具抗跌性。

土耳其保健領域不健全，成長潛能最大，隨著伊麗莎白諾維娜（Mount Elizabeth Novena）醫院及Acibadem安卡拉醫院近期開始收支平衡，綜合保健控股放眼Acibadem博德魯姆醫院也將於今年達到同樣業績。

伊麗莎白諾維娜醫院正為更佳運作效率鋪路，病床使用率超過50%，逐步增加的150張病床料於2014財政年達到70至75%使用率，進一步催化該股。

至於新加坡市場，大馬研究認為，由於佔海外病患50%的印尼客戶對匯率敏感，在印尼盾兌新元進一步貶值及其他地方提供更廉宜選擇的情況下，可能導致印尼的營業額放緩。

另外，與上海國際醫藥區（預計於2014年營業）的醫院管理及諮詢協議將是該集團的測試案列，因該醫院採取私人保健模式（駐院專科醫生），與中國傳統的保健系統（全科醫生）對衝。

至於另外一個催化因素是來自香港（預計於2017年投運），料提供比新加坡高約25%的醫藥費，更重要的是，香港市場也有助於綜合保健控股滲透中國市場。

鑒於估值高於同儕及多數正面因素已反映於股價、目標價及估值上揚空間空有限，大馬研究維持綜合保健控股“持有”評級，目標價3令吉80仙。（星洲日報／財經‧報道：郭曉芳）

icy97

IHH HEALTHCARE BERHAD

Type	Announcement
Subject	OTHERS
Description	INTERNAL REORGANISATION OF GROUP STRUCTURE
Pursuant to Paragraph 9.19(5) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of IHH Healthcare Berhad (“IHH”) is pleased to announce that Parkway Pantai Limited (“PPL”), an indirect wholly-owned subsidiary of the Company has on 12 November 2013, acquired 2 ordinary shares of RM1/- each, representing 100% of the total issued and paid-up share capital of Pantai Diagnostics Indonesia Sdn Bhd ("PDI”) from Pantai Holdings Berhad (“PHB”), an indirect wholly-owned subsidiary of PPL, for a total cash consideration of RM2/- (“Internal Reorganisation”). PDI was incorporated on 3 May 2002 and its authorised and paid-up share capital are RM100,000/- and RM2/- respectively. PDI is presently dormant and its intended principal activity is investment holding. Upon completion of the Internal Reorganisation, PDI has become a direct subsidiary of PPL. The Internal Reorganisation is not expected to have any effect on the issued and paid-up capital of IHH or IHH’s substantial shareholders’ shareholdings or any effect on the earnings, net assets or gearing of IHH on a consolidated basis. None of the directors or substantial shareholders of IHH or persons connected with them has any interest, whether direct or indirect in the Internal Reorganisation.

icy97

綜合保健第三季淨利揚61%

2013-11-27 10:33      
（吉隆坡26日訊）歸功於現有業務持續增長，以及新醫院表現強勁，拉動綜合保健（IHH，5225，主板貿服組）截至2013年9月30日止第三季淨利增長61.15%至1億1千702萬9千令吉，但首9個月淨利則倒退32.5%至4億零105萬9千令吉。

若扣除前期脫售醫療套房所兌現的1億9千360萬令吉淨利，綜合保健第三季淨利增長63%至1億3千830萬令吉。

第三季營業額為16億7千171萬8千令吉，按年走揚12.65%，首9個月營業額則下跌8.44%至49億7千631萬8千令吉。

綜合保健旗下各業務臂膀表現持續轉強，其中百匯班台營業額按年成長15%，土耳其Acibadem醫院則成長10%，教育業務臂膀――國際醫療大學（IMU）則寫下8%成長。

該公司董事經理林焯彬醫生透過文告說，營業額延續上漲勢頭，以及強勁病患人數增長和新醫院到位將可滿足市場對高品質醫療保健需求，將對集團帶來正面效益。

“我們將繼續評估國內和關鍵市場的機會，並善加利用，同時也將延續合理化營運成本、改善成本效率等措施。”

展望未來，他說，綜合保健預期國內市場今年病患人數將持續增長，並相信上軌的新工程建設計劃將可繼續滿足追求高品質醫療保健服務的需求。

其中，Acibadem安卡拉（Ankara）、博德魯姆（Bodrum）和哈卡立（Halkali）將擴大土耳其病患人數，而Acibadem也獲批在伊斯坦布爾興建兩所新醫院。

但他也指出，集團緊密關切通膨壓力對租金和其他營運成本，以及高薪留才與吸引人才的影響，而隨著集團積極探討亞洲、東歐、中東北非等地區增長機會，也將對各國匯率風險保持警惕。（星洲日報／財經）

SUMMARY OF KEY FINANCIAL INFORMATION 30/09/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/09/2013	30/09/2012	30/09/2013	30/09/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	1,671,718	1,483,937	4,976,318	5,434,753
2	Profit/(loss) before tax	169,638	119,545	591,367	840,305
3	Profit/(loss) for the period	127,542	91,481	474,867	681,735
4	Profit/(loss) attributable to ordinary equity holders of the parent	117,029	72,622	401,059	594,290
5	Basic earnings/(loss) per share (Subunit)	1.44	0.95	4.95	8.99
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.2000		2.1300

icy97

綜合保健擴張或侵蝕賺益

2013-11-27 17:55      
（吉隆坡27日訊）綜合保健控股（IHH，5225，主板貿服組）首9個月淨利按年增長45.3%符合預期，分析員多維持今年財測，惟提醒擴張醫院與激增的資本開銷，短至中期將侵蝕營運賺益與整體盈利。

馬銀行研究說：“我們發現到資本開銷由上季的27億5千萬令吉，增至今季的38億令吉，這增加擴張成本和使盈虧表受壓，總債務也由41億5千萬令吉增至48億令吉，利息負擔大增。”

財測不變

該行維持2013財政年財測不變，削減2014與2015財政年財測4%與10%；緊隨資本開銷今季調高，擴張風險將累積，未來盈利令人失望的累積風險擴大。

大眾研究預期，擴充醫院的各種成本、折舊與融資成本，短至中期將侵蝕營運賺益和整體盈利。

大馬百匯班底在大馬擴充原有檳城鷹閣醫院、吉隆坡班底醫院、巴生班底醫院與增建亞庇、曼絨、Medini新醫院。土耳其除擴充兩間原有醫院，亦增建一新醫院。

肯納格研究說，新元走挺、馬幣與印尼盾各劇跌，短至中期新加坡綜合保健將受衝擊。印尼與大馬醫藥旅遊人數各佔18%與4%。

豐隆研究說，第三季醫藥旅遊不受影響，儘管新幣上揚，醫藥旅遊仍按季上揚9%，第四季更將趁勢增長。“通膨壓力加重，面臨薪資成本增長以留人之窘境，未來營運盈利或受壓。”

興業研究說，其股價已高於一年後本益比，預期不會增派息，主要是大部份現金將作為資本開銷，第四季至2016年資本開銷達38億7千萬令吉。

安聯研究說，新加坡、大馬與土耳其單季入院病黎各按年增長7.1%、8.9%與5.9%。“其中新加坡業務受去年6月啟業的Novena醫院驅動，營運盈利1千190萬令吉，首3季營運盈利達1千150萬令吉；新元走高、收費因通膨調高及更多複雜醫案是驅動每病黎營業額增長6.5%至2萬1千519令吉之主因。”（星洲日報／財經‧報道：張啟華）

perfectevo

这个股票现在很低了，还会上吗 ？

Andy66888

走得快，好世界，好彩拜一就放了！

yeofang

perfectevo 发表于 19-12-2013 08:55 AM
这个股票现在很低了，还会上吗 ？

短期内应该不会上。 大股东都 "狂" 售了。 大雨欲来风满楼。。。

Date of Dealing	Consideration per Share	Number of Ordinary Shares	% Issued Share Capital	Nature of Transaction
9 December 2013	RM4.04	98,000	0.0012	Disposal through open market

2 December 2013

RM4.0627

1,000,000

0.0123

Disposal through open market

3 December 2013

RM4.07

200,000

0.0025

Disposal through open market

29 November 2013	RM4.050	148,900	0.0018	Disposal through open market
2 December 2013	RM4.080	89,100	0.0011	Disposal through open market

29 November 2013

RM4.0405

1,000,000

0.0123

Disposal through open market

有毛的球

奇怪，最近EPF不是在大量进票吗，怎么股价还是扶不起来

perfectevo

我也是奇怪。他们应该不会看错。要起了？

icy97

IHH HEALTHCARE BERHAD

Type	Announcement
Subject	OTHERS
Description	IHH HEALTHCARE BERHAD (“IHH” OR THE “COMPANY”) INTERNAL REORGANISATION OF IHH’S GROUP STRUCTURE
Pursuant to Paragraph 9.19(5) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of IHH (“Board”) is pleased to announce the following: (a)      Merger of Acibadem Saglik Hizmetleri ve Ticaret A.S. (“Acibadem”) with Yeni Saglik Hizmetleri ve Ticaret A.S. (“Yeni Saglik”) (“Yeni Saglik Merger”); and (b)      Merger of Acibadem with Turuncu Grup Saglik Hizmetleri Danismanlik Insaat Ticaret A.S. (“Turuncu”) (“Turuncu Merger”), had been completed on 24th December 2013. Both Yeni Saglik Merger and Turuncu Merger are collectively referred to as the “Internal Reorganisation”. Please refer to the attached document for further details.

Attachments Announcement (Merger ASH-Yeni Sağlık-Turuncu).pdf

perfectevo

你们觉得这个股如何？ 是不是要起了

icy97

Changes in Sub. S-hldr's Int. (29B)

IHH HEALTHCARE BERHAD

Particulars of substantial Securities Holder

Name	Pulau Memutik Ventures Sdn Bhd
Address	Level 33, Tower 2, Petronas Twin Towers, Kuala Lumpur City Centre, 50088 Kuala Lumpur.
NRIC/Passport No/Company No.	887202-X
Nationality/Country of incorporation	Malaysia
Descriptions (Class & nominal value)	Ordinary shares of RM1.00 each
Name & address of registered holder	Pulau Memutik Ventures Sdn Bhd Level 33, Tower 2, Petronas Twin Towers, Kuala Lumpur City Centre, 50088 Kuala Lumpur.

Details of changes

Currency: Malaysian Ringgit (MYR)

Type of transaction	Date of change	No of securities	Price Transacted (RM)
Others	20/01/2014	75,000,000

Description of other type of transaction	Please refer to column "Circumstances by reason of which changed has occured"
Circumstances by reason of which change has occurred	Return of shares from Deutsche Bank AG, London Branch ("DB") made pursuant to the Securities Lending Agreement dated 18 October 2013 between Pulau Memutik Ventures Sdn Bhd and DB
Nature of interest	Direct
Direct (units)	3,580,570,634
Direct (%)	44.01
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Total no of securities after change	3,580,570,634
Date of notice	20/01/2014

foxycuttie

中国香港的禽流感会不会刺激这支股上升？